Results 1 to 10 of about 26,607 (119)
Atypical femoral fracture: The periprosthetic variant about two cases without bisphosphonate use [PDF]
SICOT-JAtypical femoral fractures are rare. They are well described in patients with prolonged bisphosphonate use. The periprosthetic form without bisphosphonate intake appears to be exceptional and may lead to mechanical complications (nonunion, secondary ...
Auberger Guillaume +4 more
doaj +2 more sources
Frontiers in Medicine, 2021 Bisphosphonate has great potential in KOA therapy, but whether the anti-resorption mechanism of bisphosphonate aggravates sclerosis of subchondral bone remains unclear.
Mingyang Li +7 more
doaj +1 more source
Risk factors for medication-related osteonecrosis of the jaw and salivary IL-6 IN cancer patients
Brazilian Journal of Otorhinolaryngology, 2022 Introduction: Medication-related osteonecrosis of the jaws is a severe complication of the use of antiresorptive and antiangiogenic therapy, with limited treatment options and great impact on patient’s quality pf life.
Aristilia Pricila Tahara Kemp +7 more
doaj +1 more source
How much we know about bisphosphonate lesions [PDF]
Acta Stomatologica Naissi, 2016 Introduction: Bisphosphonate drugs are used in the treatment of the osteoporosis and malignant processes in the bone tissue. As a result of this use bisphosphonate lesions are formed in bone tissue and oral mucosis, which representing a remarkable ...
Pešić Zoran +2 more
doaj +1 more source
Medical and Health Science Journal, 2020 INTRODUCTION Osteogenesis imperfecta (OI) or brittle bone disease is a connective tissue formation disorder that is generally characterized by bone fragility, osteopenia, blue sclera, dentinogenesis imperfecta (DI), and hearing loss.
Baskoro Kusumo Riswanto +1 more
doaj +1 more source
Bone Quality and Fractures in Women With Osteoporosis Treated With Bisphosphonates for 1 to 14 Years
JBMR Plus, 2021 Oral bisphosphonates are the primary medication for osteoporosis, but concerns exist regarding potential bone‐quality changes or low‐energy fractures.
Hartmut H Malluche +5 more
doaj +1 more source
Topical zoledronic acid decreases micromotion induced bone resorption in a sheep arthroplasty model
BMC Musculoskeletal Disorders, 2017 Background Initial micromotion of a total hip replacement is associated with aseptic loosening. The use of bisphosphonates could be one way to reduce peri-implant bone resorption induced by micromotion.
Thomas Jakobsen +5 more
doaj +1 more source
Dose-Intensity of Bisphosphonates and the Risk of Osteonecrosis of the Jaw in Osteoporosis Patients
Frontiers in Pharmacology, 2018 Objective: To examine the incidence rates and association between dose-intensity, stratified by exposure duration, of bisphosphonates and the risk of osteonecrosis of the jaw among Korean osteoporotic patients older than 50 years.
Sung-mok Jung +2 more
doaj +1 more source
Drugs in Context, 2020 Background: On stopping bisphosphonate treatment, bone resorption may increase before evidence of a decrease in bone density. Offset of bisphosphonate effect may therefore be monitored by measuring C-terminal telopeptide (CTX) following long-term ...
Louise Statham +2 more
doaj +1 more source
Association between bisphosphonate use and COVID-19 related outcomes
eLife, 2023 Background: Although there are several efficacious vaccines against COVID-19, vaccination rates in many regions around the world remain insufficient to prevent continued high disease burden and emergence of viral variants.
Jeffrey Thompson +11 more
doaj +1 more source